Core Insights - The company achieved 9% organic constant currency revenue growth in Q4, marking 10 consecutive quarters of underlying growth driven by the U.S. farm and pet health sectors [1] Revenue Performance - Innovation revenue reached $892 million in 2025, outperforming expectations due to the rapid adoption of the 'Big Six' products, particularly Credelio Quattro and Zenrelia [1] - Credelio Quattro has become the fastest blockbuster in company history, gaining significant share in the $1.4 billion U.S. broad-spectrum parasiticide market through its unique four-ingredient differentiation [1] - Zenrelia is exceeding international expectations with double-digit market share in key regions like Brazil and Japan, driven by superior efficacy recognized by veterinarians [1] Sector Growth - U.S. Farm Animal growth of 17% was propelled by market leadership in cattle with Experior and Pradalex, despite historically small herd sizes [1] Strategic Initiatives - The 'no-regret' launch strategy, supported by expanded sales teams and DTC investment, is successfully converting innovation into market share gains across all major categories [1] - Operational efficiency and strong cash focus improved the net leverage ratio to 3.6x ahead of internal timelines, while the new Elanco Ascend initiative is set to drive further efficiencies starting in 2026 [1]

Financial Data and Key Metrics Changes - Elanco reported $1.14 billion in revenue for Q4 2025, a 12% increase year-over-year, with 9% organic constant currency growth driven primarily by volume increases [23][24] - Full-year revenue reached $4.715 billion, representing a 6% growth, with Adjusted EBITDA of $901 million and Adjusted EPS of $0.94, compared to $0.91 in 2024 [26][27] - The net leverage ratio improved to 3.6 times at year-end, with expectations to reduce it to 3.1-3.3 times in 2026 [6][28] Business Line Data and Key Metrics Changes - U.S. Pet Health revenue grew 10% in Q4, driven by innovation products like Credelio Quattro and Zenrelia, while international pet health grew 8% [23][24][9] - U.S. Farm Animal business achieved a 17% growth in Q4, with strong contributions from Experior and Pradalex, while international farm animal grew 4% [24][9] - Innovation revenue for 2025 was $892 million, with expectations to reach $1.15 billion in 2026 [5][10] Market Data and Key Metrics Changes - The U.S. broad-spectrum parasiticide market grew 30% year-over-year, with Credelio Quattro gaining significant market share [12][11] - Zenrelia achieved over 30% market share in Japan and 40% in Brazil, indicating strong international performance [15][42] - The overall animal health market is projected to add $20 billion in value over the next decade, with Elanco positioned to capitalize on this growth [34] Company Strategy and Development Direction - Elanco's strategy focuses on growth, innovation, and cash management, with a commitment to introducing new products and enhancing operational efficiency [5][21] - The company is expanding its leadership in the dairy industry through the acquisition of AHV International, which will enhance its portfolio and market presence [20][21] - Elanco Ascend, a productivity initiative, aims to drive efficiencies and margin enhancements starting in 2026 [32] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in Elanco's trajectory, highlighting strong momentum and a commitment to transforming animal care [33][38] - The company anticipates sustainable revenue growth driven by innovation and strategic pricing, despite competitive pressures [31][36] - Management acknowledged the importance of adapting to changing consumer behaviors in both pet health and farm animal sectors [35][37] Other Important Information - Adjusted gross margin increased to 51.2% in Q4, driven by price and volume increases, while operating expenses grew by 10% to support strategic investments [24][25] - The effective tax rate for 2025 was 21.8%, reflecting a year-over-year increase due to non-recurring tax credits recognized in 2024 [27] Q&A Session Summary Question: Insights on Zenrelia's international share gains - Management noted that Zenrelia's efficacy is increasingly recognized, leading to significant share gains in international markets like Japan and Brazil, with expectations for continued growth in the U.S. [41][42][44] Question: Impact of Covetrus and MWI merger on Elanco - Management emphasized strong relationships with distributors and the value they add, indicating confidence in maintaining competitive advantages despite market changes [48][49] Question: Clarification on pricing strategy for 2026 - Management confirmed expectations for accelerating price growth in 2026, driven by the value of new innovations and a comprehensive portfolio [54][56] Question: Stocking dynamics and competitive positioning in parasiticides - Management reported strong dispensing demand with no significant stocking issues, indicating a solid position in the parasiticides market [65][66] Question: Timeline for Zenrelia label update in the U.S. - Management is in constructive dialogue with the FDA regarding the label update, with confidence in achieving alignment with international standards [68][70]

Core Viewpoint - Elanco Animal Health Incorporated has released its 2024 Impact Report, emphasizing its commitment to enhancing animal care and the well-being of those who care for them through a new framework focused on four key communities of impact [1][2][3] Group 1: Commitment to Animals - Elanco's strong portfolio and high-impact innovations drive the company's mission to improve animal lives [4] - Key innovations such as Zenrelia, Credelio Quattro, and Pradalex generated $461 million in revenue in 2024, exceeding the target of $420 million to $450 million [7] - The company ranked as the 1 retail parasiticide dispenser in the U.S. and expanded global retail offerings [7] Group 2: Commitment to Customers - Elanco aims to advocate for and earn the trust of customers while solving significant challenges to create value [5] - The company has launched new veterinary-formulated pet supplements under the Advantage family umbrella [7] Group 3: Commitment to Society - Elanco is dedicated to improving public health through animal health initiatives and safeguarding the food system [6] - The company donated over $400,000 worth of products to support animal health and well-being [7] - Elanco's UpLook database helps U.S. dairy farmers earn around $10 million in net returns from carbon credit reductions [7] Group 4: Commitment to Employees - Elanco promotes a purpose-driven culture that encourages ownership, growth, and well-being among its employees [8] - The company achieved a 71% Employee Engagement Score, reflecting a 4% increase from the previous year [11] - Over 26,000 volunteer hours were recorded in 2024, contributing an estimated value of $870,000 across 1,100 global organizations [11] Group 5: Future Outlook - Elanco invites stakeholders to explore the full 2024 Impact Report and is committed to advancing its purpose of making life better for animals, customers, society, and employees [9]